Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Two-Way Crossover Study to Investigate the Potential Pharmacokinetic Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants

Next Previous
Search
Trial Profile

An Open-Label, Randomized, Two-Way Crossover Study to Investigate the Potential Pharmacokinetic Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethinylestradiol/levonorgestrel (Primary) ; Padsevonil (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Sponsors UCB Biopharma

    • Most Recent Events

    • 09 Jun 2020 Status changed from suspended to discontinued, as UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures.
    • 20 May 2020 Outcome measures, arms and interventions amended.
    • 03 Apr 2020 Status changed from recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top